SCHEMBL4496285

SCHEMBL4496285

Cc1ccc(N)cc1-c1ccc2c(c1)CN(c1ccccc1)C2=O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 6/20 0.51
RAB9A P51151 6/20 0.51
PKM P14618 3/20 0.47
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
ALDH1A1 P00352 2/20 0.42
TSHR P16473 2/20 0.42
CASP1 P29466 2/20 0.42
MAPK1 P28482 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
PIK3CG P48736 2/20 0.41
CYP11B2 P19099 3/20 0.40
TP53 P04637 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
CYP2D6 P10635 2/20 0.40
CYP11B1 P15538 2/20 0.40
LMNA P02545 1/20 0.40
CYP2C19 P33261 1/20 0.40
ANPEP P15144 1/20 0.40
DPP4 P27487 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4501822 0.84 MAP3K5 (0.49) NPC1RAB9APKMMEN1KMT2A
SCHEMBL14259445 0.84 NPC1 (0.67) NPC1RAB9APKMMEN1KMT2A
SCHEMBL28625588 0.80 NPC1 (0.65) NPC1RAB9APKMMEN1KMT2A
SCHEMBL3055917 0.79 NPC1 (0.47) NPC1RAB9APKMMEN1KMT2A
SCHEMBL7233060 0.78 NPC1 (0.67) NPC1RAB9APKMMEN1KMT2A
SCHEMBL4503641 0.78 MAPK14 (0.53) CYP2C19RAF1
SCHEMBL17067786 0.77 NPC1 (0.67) NPC1RAB9APKMMEN1KMT2A
SCHEMBL4506375 0.75 MAPK14 (0.52) NPC1RAB9AMEN1KMT2A
SCHEMBL4503646 0.75 MAPK14 (0.61)
SCHEMBL4505710 0.74 MAPK14 (0.51) RAB9ATP53RAF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090286775-A1 Bicyclic Derivatives as P38 Kinase Inhibitors PALAU PHARMA, S.A. (ES) 2009-11-19 US disclosed
EP-1917241-A2 BICYCLIC DERIVATIVES AS P38 KINASE INHIBITORS Palau Pharma, S.A. (ES) 2008-05-07 EP disclosed
WO-2007000339-A1 BICYCLIC DERIVATIVES AS P38 KINASE INHIBITORS PALAU PHARMA, S.A. (ES) 2007-01-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286775-A1 Bicyclic Derivatives as P38 Kinase Inhibitors MAPK1, MAPKAPK2, MAPKAPK3 NPC1 2214/4885RAB9A 1683/4885PKM 788/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.